STOCK TITAN

Claritas Pharmaceuticals (KALTF) Stock News, Feb-Mar 2021

KALTF OTC
Rhea-AI Summary

Claritas Pharmaceuticals, previously Kalytera Therapeutics, has forged a Strategic Collaboration Agreement with the Salzman Group to fast-track the development of its nitric oxide-releasing compound, R-107. This initiative aims to expedite the manufacturing and clinical studies of R-107, targeting COVID-19 and other viral infections. The partnership leverages expertise from notable scientists, reducing costs and enhancing developmental efficiency. Claritas plans to initiate Phase 1 clinical studies in Australia and is set to benefit from R&D tax credits, positioning itself strategically in the biotech sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
-
Rhea-AI Summary

Claritas Pharmaceuticals (formerly Kalytera Therapeutics) announced significant findings regarding its nitric oxide-releasing compound, R-107, for treating COVID-19. Clinical data from Massachusetts General Hospital showed viral clearance in 5 of 6 pregnant patients after inhaling nitric oxide gas, with no other antiviral treatment. Additionally, studies indicated over 99.9% inhibition of SARS-CoV-2 reproduction in vitro. The CEO emphasized the potential of R-107 in managing vaccine-resistant strains and improving COVID-19 mortality. Claritas aims to prioritize R-107's development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
-
Rhea-AI Summary

Claritas Pharmaceuticals (formerly Kalytera Therapeutics) has announced a strategic focus on R-107, a nitric oxide-releasing compound aimed at treating vaccine-resistant COVID-19 and other viral infections. R-107 can be administered orally, nasally, or via injection, providing a broader systemic effectiveness than traditional nitric oxide therapies. The company collaborates with the Salzman Group to develop R-107 for both treatment and potential prevention of viruses. Claritas aims to position R-107 as a leading antiviral therapy, emphasizing its significant antiviral properties against various RNA viruses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
Rhea-AI Summary

Kalytera Therapeutics, Inc. will change its name to Claritas Pharmaceuticals and launch a new website, pending TSX VENTURE EXCHANGE approval. The new focus includes the development of R-107, a nitric oxide-releasing molecule targeting vaccine-resistant COVID-19 and other viral infections. The ticker symbol will also change accordingly. The company emphasizes R-107’s ease of administration compared to traditional nitric oxide therapies. Claritas aims to address significant unmet medical needs, with plans to continuously update its website with relevant news and developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none